Thank you. Operator. Good afternoon. Good morning, and a warm welcome to the Egetis Therapeutics second quarter results webcast, which is planned for the coming 30 minutes. For those whom I haven't had the privilege to meet before, my name is Nicklas Westerholm, and I am the CEO of the company. I will start today's session with a short business update. This will be followed by Anny Bedard, President of our U.S. And North American business, who will discuss the launch preparations for the planned Emcitate launch in the US, subject to approval. Then, Henrik Krook, Vice President, Commercial Operations, will give a commercialization update of Emcitate in the European Union, as well as other international markets. Finally, Yilmaz Mahshid, Chief Financial Officer, will provide a financial update before we look ahead to the exciting upcoming key value-enhancing milestones; we aim to leave ample time for Q&A at the end of the session. The most significant event during the first half of 2026 was the acceptance of our US New Drug Application, NDA, for Emcitate. The grant of a priority review by the FDA with a PDUFA date set for the 28th of September. So far, it has been a collaborative dialogue with the agency throughout the review. The FDA has confirmed that it expects to finish its review by the PDUFA date on the 28th of September, and does not plan to hold an advisory committee meeting, subject to approval. The Emcitate launch in the US is planned for the fourth quarter of this year. We were also granted our first patent for Emcitate by the US Patent and Trademark Office. The patent provides protection for a novel composition with tiratricol as the active ingredient. The claims cover, amongst other things, a method of treatment for MCT8 deficiency with the claimed pharmaceutical composition that encompasses tiratricol dosing regimens and tiratricol compositions with specific excipients. This patent is a significant milestone in strengthening our intellectual property portfolio. We expect the granted patent to be Orange Book listed with an expiration date of 2045. Revenue for the second quarter was 17.4 million MSEK, corresponding to year-on-year growth of 23% at a constant exchange rate. As Henrik will describe further, the Emcitate price negotiations within the German reimbursement process, AMNOG, were successfully concluded in the second quarter. Furthermore, in the quarter, we also successfully carried out a substantially oversubscribed directed share issue amounting to 350 million Swedish kronor, approximately 38 million USD at the closing price on Nasdaq Stockholm on the day of the raise. We were particularly pleased to see strong participation from both existing shareholders and several new international specialist healthcare investors, which will further broaden our shareholder base. Last but not least, we are pleased to welcome Tiago Nunes, a very seasoned drug developer, as our new Chief Medical Officer in May. One of Tiago's main tasks will be to drive Emcitate's exciting indication expansion opportunity in resistance to thyroid hormone beta forward in the short-term future. I will now hand over to Anny. Anny, please go ahead.